Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer, Chemotherapy Effect
Delayed SLND for Patients With Breast Cancer Undergoing Primary Systemic Treatment
The goal of this study was to assess the feasibility of SLND by superparamagnetic iron oxide nanoparticles (SPIO) in patients with early breast cancer planned for primary systemic therapy (PST) and whether this is affected by the…
- Conditions
- Breast Cancer, Chemotherapy Effect, Sentinel Lymph Node
- Trial name
- MagNeo (NCT05985551)
- Testing
- SLND or TAD by the magnetic technique (SPIO)
- Where
- Sweden
- Volunteers
- 114 people
- Sponsor
- Uppsala University
Breast Cancer Early Stage Breast Cancer (Stage 1-3), HER2
A Composite Assay for HER2-positive Early-stage Breast Cancer Management
The goal of this observational study is to assess the prognostic value of a genomic classifier (S18) and its refined version (S*) in women with early-stage HER2-positive breast cancer.
- Trial name
- HERCard (NCT06762977)
- Where
- 2 sites in Italy
- Volunteers
- 180 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lymphedema, Breast Cancer Stage II
Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related Lymphoedema
The goal of the study is to investigate the use of bio-impedance spectroscopy in the assessment of breast cancer related lymphoedema in patients operated with lumpectomy or mastectomy, axillary lymph node dissection and…
- Conditions
- Lymphedema, Breast Cancer Stage II, Early Disease Onset
- Trial name
- NCT01599039
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Nij Smellinghe Hosptial
Breast Cancer
Supplemental Screening for Women With Extremely Dense Breast Tissue: the DENSE-2 Trial
Women with extremely dense breasts (nearly all glandular and connective tissue, little fatty tissue) have a 3-6 times higher risk of breast cancer than women with very low breast density.
- Trial name
- DENSE-2 (NCT06636370)
- Testing
- Contrast-enhanced mammography (CEM), Abbreviated MRI (AB-MRI)
- Where
- Netherlands
- Volunteers
- 36,000 people, healthy volunteers welcome
- Sponsor
- C.H. van Gils
HER2-normal
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
The purpose of this study is to assess the feasibility of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate for adjuvant treatment of early stage breast cancer.
- Trial name
- NCT01328249
- Testing
- eribulin mesylate
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eisai Inc.
Breast Cancer
Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia
This is a retrospective, multicenter study, consisting of chart review of Saudi Arabian participants diagnosed with breast cancer between 2007 and 2013 and with available human epidermal growth factor receptor 2 (HER2) testing.
- Trial name
- NCT02954471
- Where
- 3 sites in Saudi Arabia
- Volunteers
- 351 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer
Longitudinal Evaluation of Taxane induced neuropathy in early stage breast cancer.
- Trial name
- NCT02125019
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
In this open-label multicenter trial, participants with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (4 cycles of docetaxel followed by 4 cycles of…
- Trial name
- NCT00950300
- Testing
- 5-Fluorouracil, Cyclophosphamide, Docetaxel
- Where
- 106 sites in Argentina, Brazil and 24 more
- Volunteers
- 596 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, DCIS
CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)
This study will prospectively evaluate the technical feasibility, acute toxicity, late effects and oncologic outcomes of CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI) in early stage breast cancer.
- Conditions
- Breast Cancer, DCIS, Invasive Ductal Carcinoma
- Trial name
- CK-SAPBI (NCT02365714)
- Testing
- CK Stereotactic Accelerated Partial Breast Irradiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Georgetown University
Early Breast Cancer
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
This is a randomized, multicenter, open-label, two-arm, Phase II study to evaluate the efficacy, safety, and pharmacokinetics of giredestrant versus anastrozole (in the window-of-opportunity phase) and giredestrant plus…
- Trial name
- NCT04436744
- Testing
- Giredestrant, Anastrozole, Palbociclib
- Where
- 65 sites in United States, Australia and 9 more
- Volunteers
- 221 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Chemotherapy Induced Systolic Dysfunction
Early Detection of CMP in Patients With Breast Cancer Using Cardiac Magnetic Resonance
Breast cancer is the most common cancers among women worldwide.Although chemotherapy and surgery have greatly improved the survival rate, most types of chemotherapy have been reported to have varying degrees of cardiotoxicity.
- Trial name
- NCT04510532
- Testing
- CMR examination
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Breast Neoplasms, Breast Diseases
Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients with Small Breast Cancer
This prospective, multicentric single arm phase II study is based on the protocol of the international TARGIT-A study. The purpose is to investigate the efficacy of a single intraoperative radiotherapy treatment within elderly…
- Conditions
- Breast Neoplasms, Breast Diseases, Neoplasm Recurrence, Local, Neoplasms
- Trial name
- TARGIT-E (NCT01299987)
- Testing
- intraoperative radiotherapy
- Where
- Germany
- Volunteers
- 591 people
- Sponsor
- Universitätsmedizin Mannheim
Early Breast Cancer, Premenopausal Breast Cancer
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
Rationale: Around 70 to 80% of breast cancers are so-called "hormone-dependent" (HR+)/HER2-. For more than 50 years, studies have shown that chemotherapy and optimised hormonal treatments (hormone therapy), including a drug…
- Conditions
- Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer
- Trial name
- OPTIMA-YOUNG (NCT07106632)
- Testing
- test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone, In the control arm, the treatment will be as standard of care : chemo-endocrine therapy
- Where
- 105 sites in Belgium, France and 5 more
- Volunteers
- 3,380 people
- Sponsor
- UNICANCER
Breast Cancer, HR+/HER2- Early-Stage
Predicting Recurrence in HR+/HER2- Early Breast Cancer
Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer constitutes approximately 70% of all breast cancer cases.
- Trial name
- NCT07484763
- Volunteers
- 500 people
- Sponsor
- Shengjing Hospital
Breast Cancer
CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer
The investigators designed a phase III clinical trial involving hormone receptor-positive and HER2-positive stage I breast cancer patients.
- Trial name
- Cinderella (NCT07213206)
- Testing
- CDK 4/6 inhibitor combined therapy (omit chemo), standard of care
- Volunteers
- 1,500 people
- Sponsor
- Fudan University
Breast Cancer
Internal Mammary Sentinel Lymph Node Biopsy With Modified Injection Technique
Internal Mammary Lymph Node (IMLN) and Axillary Lymph Node (ALN) are regarded as "the first station" of lymphatic drainage in breast cancer, serving as an important reference for lymph staging and decision-making.
- Trial name
- NCT03541278
- Testing
- MIT, IM-SLNB
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Shandong Cancer Hospital and Institute
Triple Negative Breast Cancer
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
Patients with stage II-III Triple negative breast cancer (TNBC) candidates to receive neoadjuvant chemotherapy (NACT) +/- immune checkpoint inhibitor (ICI) will be included.
- Trial name
- PORTRAIT (NCT05916755)
- Testing
- Whole Genome Sequencing, RNA-Sequencing, Microbiome analysis
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Breast Cancer
Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients
Late Cardiac Evaluation of the Three Arm Belgian Trial A phase III randomized trial involving node-positive early breast cancer patients with a long median follow-up (~ 15 years) OBJECTIFS Primary: To compare the incidence of…
- Trial name
- NCT01554943
- Testing
- cardiac MRI
- Where
- Belgium
- Volunteers
- 73 people
- Sponsor
- Jules Bordet Institute
Breast Cancer
Colombian Screening Mammography Project
A cluster randomized controlled trial was performed in Bogotá, Colombia between 2007-2008 to evaluate the effects of an opportunistic (hospital-based) screening program (intervention) vs.
- Trial name
- NCT02337582
- Testing
- Opportunistic Breast cancer screening, Usual Care
- Where
- United States
- Volunteers
- 15,855 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Triple Negative Breast Cancer
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
The study hypothesise that the combination of carboplatin, gemcitabine, bevacizumab and atezolizumab may be synergistic and improve outcomes for patients with early relapsed TNBC by overcoming mechanisms of immune resistance and…
- Trial name
- BELLA (NCT04739670)
- Testing
- Atezolizumab, Bevacizumab, Gemcitabine
- Where
- 4 sites in Australia
- Volunteers
- 31 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.